Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

We recently published 10 Big Names Beating Wall Street at its Own Game. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Monday. Recursion Pharmaceuticals soared by 13.99 ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.75, demonstrating a -5.89% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 45,210 calls trading, 6x expected, and implied vol increasing over 39 points to 162.61%. Jan-26 7.5 calls and Oct-25 7 calls are ...

Transaction value is based on the SEC Form 4 weighted average purchase price ($6.04) as reported for the transaction on October 10, 2025. How does the scale of this transaction compare to Christopher ...